Compare iShares MSCI South Korea ETF (EWY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Sana Biotechnology Inc — how do they compare? iShares MSCI South Korea ETF trades at $177.22 (market cap $26.25B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: iShares MSCI South Korea ETF is far larger — about 31.4× Sana Biotechnology Inc's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 47 Days and Sana Biotechnology Inc for 23 Days on average.
| EWY | SANA | |
|---|---|---|
Market Cap | $26.25B | $836.71M |
Volume | 19,056,075 | 4,507,444 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $5.92 |
52-Week Low | $80.72 | $2.68 |
Typical Hold Time | 47 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY is trading at $176.33, down 4.02% amid bearish technical signals, with moving averages indicating selling pressure. The ETF faces headwinds from rising US yields and oil prices impacting South Korean tech stocks, though RSI levels suggest potential oversold conditions. Recent volatility reflects sensitivity to AI sector dynamics and global macroeconomic factors.
Outlook remains cautious due to concentrated exposure to semiconductor giants Samsung and SK Hynix, creating dependency on memory cycle strength. Investment opportunity exists if AI demand sustains earnings growth, but risks include Fed policy impacts and geopolitical tensions. Governance reforms and deleveraging provide fundamental support amid market turbulence.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
